Phathom Pharmaceuticals Inc (OQ:PHAT)

Business Focus: Biotechnology & Medical Research

Apr 03, 2024 08:00 am ET
Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will participate in a fireside...
Mar 26, 2024 08:00 am ET
Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announces the launch of its new broadcast ad and full-scale,...
Mar 07, 2024 08:00 am ET
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the fourth quarter and full year ended December...
Feb 29, 2024 08:00 am ET
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:30 am ET on Thursday, March 7,...
Feb 13, 2024 08:00 am ET
Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the placement of VOQUEZNA® (vonoprazan) tablets for the treatment of...
Feb 12, 2024 08:31 am ET
Thinking about buying stock in Meta Platforms, Ocular Therapeutix, Phathom Pharmaceuticals, Revelation Biosciences, or Sunworks?
NEW YORK, Feb. 12, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for META, OCUL, PHAT, REVB, and SUNW.
Jan 31, 2024 08:00 am ET
Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will participate in a fireside...
Dec 14, 2023 08:00 am ET
Phathom Pharmaceuticals Announces Expansion of Existing Loan and Security Agreement with Hercules Capital
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced an amendment to its term loan facility from Hercules Capital, Inc....
Dec 06, 2023 08:00 am ET
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the FDA has accepted for review the company’s NDA for VOQUEZNA...
Nov 28, 2023 08:00 am ET
Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced the U.S. commercial availability of VOQUEZNA® (vonoprazan)....
Nov 21, 2023 05:42 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Phathom Pharmaceuticals, Inc. (NA
Levi & Korsinsky announces that it has commenced an investigation of Phantom Pharmaceuticals, Inc. (NASDAQ: PHAT) concerning possible breaches of fiduciary duty. To obtain additional information, go to:...
Nov 11, 2023 08:18 am ET
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) and Encourages Investors to Contact the Firm
Kaskela Law LLC announces that it is investigating Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) (“Phathom”) on behalf of the company’s investors. Since August 2023, shares of Phathom’s common stock have declined in value from a trading price of...
Nov 09, 2023 08:00 am ET
Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the third quarter of 2023 and provided updates...
Nov 01, 2023 05:00 pm ET
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today the U.S. Food and Drug Administration (FDA) has approved...
Oct 30, 2023 08:00 am ET
Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA® TRIPLE PAK® (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA® DUAL PAK® (vonoprazan, amoxicillin)
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced that the U.S. Food and Drug Administration (FDA) has approved the...
Oct 25, 2023 08:01 am ET
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of its management team are scheduled to participate in...
Oct 23, 2023 08:22 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Phathom Pharmaceuticals, Inc. (NA
NEW YORK, Oct. 23, 2023 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Phantom Pharmaceuticals, Inc. (NASDAQ: PHAT) concerning possible breaches of fiduciary duty. To obtain additional information, go to:
Sep 26, 2023 08:01 am ET
Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced the submission of an NDA to the FDA for vonoprazan as a daily...
Sep 21, 2023 03:17 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Phathom Pharmaceuticals, Inc. (NA
Levi & Korsinsky announces that it has commenced an investigation of Phantom Pharmaceuticals, Inc. (NASDAQ: PHAT) concerning possible breaches of fiduciary duty. To obtain additional information, go to:...
Sep 05, 2023 08:00 am ET
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of its management team will participate in the...
Aug 22, 2023 06:03 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Phathom Pharmaceuticals, Inc. (NA
Levi & Korsinsky announces that it has commenced an investigation of Phantom Pharmaceuticals, Inc. (NASDAQ: PHAT) concerning possible breaches of fiduciary duty. To obtain additional information, go to:...
Aug 21, 2023 08:00 am ET
Phathom Pharmaceuticals Announces Submission of Six-Month Stability Data in Support of Erosive GERD New Drug Application
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced it has submitted to the FDA six-month stability data from its...
Aug 10, 2023 08:01 am ET
Phathom Pharmaceuticals Reports Second Quarter 2023 Results
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the second quarter of 2023 and provided updates...
Jun 19, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Integra, Chinook, Phathom, and Akumin and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Integra LifeSciences Holdings Corp. (NASDAQ: IART), Chinook Therapeutics, Inc. (NASDAQ: KDNY), Phathom Pharmaceuticals, Inc....
Jun 12, 2023 08:01 am ET
Phathom Pharmaceuticals Announces FDA Acceptance of NDA Resubmission for Erosive GERD
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that the U.S. Food and Drug Administration (FDA) has acknowledged...
Jun 09, 2023 04:01 pm ET
Phathom Pharmaceuticals Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the closing of the sale of an additional 1,668,750 shares of common...
Jun 09, 2023 05:45 am ET
PHAT FRAUD ALERT: Jakubowitz Law is Investigating Phathom Pharmaceuticals, Inc. in Connection with Potential Violations of Federal Securities Laws
NEW YORK, June 9, 2023 /PRNewswire/ -- Jakubowitz Law announces that an investigation into potential securities fraud allegations has commenced on behalf of shareholders of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT)
Jun 08, 2023 05:45 am ET
PHAT INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Phathom Pharmaceuticals, Inc.
NEW YORK, June 8, 2023 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Phathom Pharmaceuticals, Inc. ("Phathom") (NASDAQ: PHAT) concerning possible violations of federal securities laws.
Jun 07, 2023 05:45 am ET
INVESTIGATION ALERT: The Gross Law Firm Notifies Shareholders of Phathom Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit - (NASDAQ: PHAT)
NEW YORK, June 7, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Phathom Pharmaceuticals, Inc.:
Jun 04, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Phathom, Reata, and Comerica and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT), Reata Pharmaceuticals, Inc. (NASDAQ: RETA), and Comerica Incorporated (NYSE:...
Jun 02, 2023 05:45 am ET
PHAT FRAUD ALERT: Jakubowitz Law is Investigating Phathom Pharmaceuticals, Inc. in Connection with Potential Violations of Federal Securities Laws
NEW YORK, June 2, 2023 /PRNewswire/ -- Jakubowitz Law announces that an investigation into potential securities fraud allegations has commenced on behalf of shareholders of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT)
Jun 01, 2023 08:00 am ET
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of its management team will participate in the...
Jun 01, 2023 05:45 am ET
PHAT INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Phathom Pharmaceuticals, Inc.
NEW YORK, June 1, 2023 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Phathom Pharmaceuticals, Inc. ("Phathom") (NASDAQ: PHAT) concerning possible violations of federal securities laws.
May 31, 2023 05:45 am ET
PHAT NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Phathom Pharmaceuticals, Inc.
NEW YORK, May 31, 2023 /PRNewswire/ -- The Klein Law Firm announces that it is investigating allegations that Phathom Pharmaceuticals, Inc. ("Phathom") (NASDAQ: PHAT) violated federal securities laws.
May 31, 2023 05:00 am ET
PHAT ALERT: The Law Offices of Vincent Wong Investigate Phathom Pharmaceuticals, Inc. for Potential Violations of Securities Laws
NEW YORK, May 31, 2023 /PRNewswire/ -- Attention Phathom Pharmaceuticals, Inc. ("Phathom") (NASDAQ: PHAT) shareholders:
May 30, 2023 11:42 am ET
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT
WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) resulting from allegations that Phathom may have issued...
May 30, 2023 05:00 am ET
PHAT FRAUD ALERT: Jakubowitz Law is Investigating Phathom Pharmaceuticals, Inc. in Connection with Potential Violations of Federal Securities Laws
NEW YORK, May 30, 2023 /PRNewswire/ -- Jakubowitz Law announces that an investigation into potential securities fraud allegations has commenced on behalf of shareholders of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT)
May 29, 2023 05:00 am ET
PHAT NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Phathom Pharmaceuticals, Inc.
NEW YORK, May 29, 2023 /PRNewswire/ -- The Klein Law Firm announces that it is investigating allegations that Phathom Pharmaceuticals, Inc. ("Phathom") (NASDAQ: PHAT) violated federal securities laws.
May 26, 2023 09:00 pm ET
PHATHOM ALERT: Bragar Eagel & Squire, P.C. is Investigating Phathom Pharmaceuticals, Inc. on Behalf of Phathom Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Phathom Pharmaceuticals, Inc. (“Phathom” or the “Company”) (NASDAQ: PHAT) on behalf of Phathom stockholders. Our...
May 26, 2023 05:20 am ET
PHAT INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Phathom Pharmaceuticals, Inc.
Levi & Korsinsky notifies investors that it has commenced an investigation of Phathom Pharmaceuticals, Inc. ("Phathom") (NASDAQ: PHAT) concerning possible violations of federal securities laws. On August 2, 2022, before market hours, Phathom...
May 26, 2023 05:00 am ET
INVESTIGATION ALERT: The Gross Law Firm Notifies Shareholders of Phathom Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit - (NASDAQ: PHAT)
NEW YORK, May 26, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Phathom Pharmaceuticals, Inc.:
May 25, 2023 08:02 pm ET
PHAT INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Phathom Pharmaceuticals, Inc.
NEW YORK, May 25, 2023 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Phathom Pharmaceuticals, Inc. ("Phathom") (NASDAQ: PHAT) concerning possible violations of federal securities laws.
May 24, 2023 11:30 am ET
Thinking about buying stock in Vita Coco, Phathom Pharmaceuticals, Avrobio, Nano-X Imaging, or Nextdoor?
NEW YORK, May 24, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for COCO, PHAT, AVRO, NNOX, and KIND.
May 23, 2023 07:41 pm ET
Phathom Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the pricing of its underwritten public offering of 11,125,000 shares...
May 23, 2023 04:01 pm ET
Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that it intends to offer and sell, subject to market and other...
May 23, 2023 04:00 pm ET
Phathom Pharmaceuticals Resubmits Erosive GERD New Drug Application to FDA
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it has resubmitted its New Drug Application (NDA) for...
May 19, 2023 09:50 pm ET
PHAT INVESTOR ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT
WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) resulting from allegations that Phathom may have issued...
May 10, 2023 08:00 am ET
Phathom Pharmaceuticals Reports First Quarter 2023 Results
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the first quarter of 2023 and provided updates...
May 09, 2023 08:00 am ET
Phathom Pharmaceuticals Presents New Data at Digestive Disease Week® (DDW) 2023
Higher H. pylori eradication rates demonstrated with vonoprazan-based regimens vs. lansoprazole triple therapy, regardless of different baseline demographics and clinical characteristicsMeta-analysis shows potassium-competitor acid blockers (PCABs),...
Apr 14, 2023 06:37 pm ET
Phathom Pharmaceuticals, Inc: Company Investigated by the Portnoy Law Firm
The Portnoy Law Firm advises Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. Phathom investors that lost money on...
Apr 12, 2023 08:00 am ET
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of its management team will participate in the...
Apr 11, 2023 02:39 pm ET
ROSEN, NATIONAL TRIAL COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT
WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) resulting from allegations that Phathom may have issued...
Apr 04, 2023 08:00 am ET
Phathom Pharmaceuticals Announces Regulatory Update and Plans for 2023 Erosive Esophagitis and H. pylori Commercial Launch
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today provided a regulatory update following its recent meeting with the FDA...
Mar 09, 2023 09:51 pm ET
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT
WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) resulting from allegations that Phathom may have issued...
Mar 01, 2023 06:26 pm ET
TOP RANKED ROSEN LAW FIRM Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT
WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) resulting from allegations that Phathom may have issued materially misleading business information to the investing public.
Mar 01, 2023 05:03 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Phathom Pharmaceuticals, Inc. - PHAT
Pomerantz LLP is investigating claims on behalf of investors of Phathom Pharmaceuticals, Inc. (“Phathom” or the “Company”) (NASDAQ: PHAT). Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext....
Feb 28, 2023 07:38 pm ET
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT
WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) resulting from allegations that Phathom may have issued...
Feb 28, 2023 08:00 am ET
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the fourth quarter and full year ended December...
Feb 14, 2023 08:40 pm ET
GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT
WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) resulting from allegations that Phathom may have issued...
Feb 14, 2023 08:17 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Phathom Pharmaceuticals, Inc. - PHAT
Pomerantz LLP is investigating claims on behalf of investors of Phathom Pharmaceuticals, Inc. (“Phathom” or the “Company”) (NASDAQ: PHAT).   Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext....
Feb 13, 2023 07:05 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Phathom Pharmaceuticals, Inc. - PHAT
NEW YORK, Feb. 13, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Phathom Pharmaceuticals, Inc. ("Phathom" or the "Company") (NASDAQ: PHAT).  Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980.
Feb 09, 2023 04:01 pm ET
Phathom Pharmaceuticals Provides Regulatory Updates
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced regulatory updates for its approved products, VOQUEZNA™ TRIPLE PAK™...
Feb 09, 2023 03:32 pm ET
TOP RANKED ROSEN LAW FIRM Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT
WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) resulting from allegations that Phathom may have issued...
Feb 06, 2023 10:53 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Phathom Pharmaceuticals, Inc. - PHAT
NEW YORK, Feb. 6, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Phathom Pharmaceuticals, Inc. ("Phathom" or the "Company") (NASDAQ: PHAT).  Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980.
Feb 04, 2023 04:52 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Phathom Pharmaceuticals, Inc. - PHAT
Pomerantz LLP is investigating claims on behalf of investors of Phathom Pharmaceuticals, Inc. (“Phathom” or the “Company”) (NASDAQ: PHAT).   Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext....
Feb 03, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Credit Acceptance, and Phathom and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Credit Acceptance Corporation (NASDAQ: CACC), and Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT). Our investigations concern...
Jan 21, 2023 10:10 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Phathom Pharmaceuticals, Inc. - PHAT
Pomerantz LLP is investigating claims on behalf of investors of Phathom Pharmaceuticals, Inc. (“Phathom” or the “Company”) (NASDAQ: PHAT).   Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext....
Jan 19, 2023 11:15 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Phathom Pharmaceuticals, Inc. - PHAT
NEW YORK, Jan. 20, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Phathom Pharmaceuticals, Inc. ("Phathom" or the "Company") (NASDAQ: PHAT). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Jan 18, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Phathom, Super Micro, and Fate and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT), Super Micro, Inc. (NASDAQ: SMCI), and Fate Therapeutics, Inc. (NASDAQ: FATE)....
Jan 17, 2023 06:50 pm ET
ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT
WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) resulting from allegations that Phathom may have issued...
Jan 11, 2023 11:21 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Phathom Pharmaceuticals, Inc. - PHAT
NEW YORK , Jan. 12, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Phathom Pharmaceuticals, Inc. ("Phathom" or the "Company") (NASDAQ: PHAT).  Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980.
Jan 11, 2023 09:00 pm ET
PHATHOM ALERT: Bragar Eagel & Squire, P.C. is Investigating Phathom Pharmaceuticals, Inc. on Behalf of Phathom Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Phathom Pharmaceuticals, Inc. (“Phathom” or the “Company”) (NASDAQ: PHAT) on behalf of Phathom stockholders. Our...
Jan 08, 2023 06:00 pm ET
Phathom Pharmaceuticals Announces Positive Topline Results from Phase 3 PHALCON-NERD-301 Trial Evaluating Daily Dosing of Vonoprazan for Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, announced today positive topline results from PHALCON-NERD-301, a...
Jan 05, 2023 04:32 pm ET
Phathom Pharmaceuticals, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses
The Portnoy Law Firm advises Phathom Pharmaceuticals, Inc. (“Phathom” or the “Company”) (NASDAQ: PHAT) investors that the law firm has initiated an investigation on behalf of investors that lost money on their Phathom Pharmaceuticals, Inc. stock....
Jan 05, 2023 10:44 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Phathom Pharmaceuticals, Inc. - PHAT
Pomerantz LLP is investigating claims on behalf of investors of Phathom Pharmaceuticals, Inc. (“Phathom” or the “Company”) (NASDAQ: PHAT). Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext....
Jan 03, 2023 04:01 pm ET
Phathom Pharmaceuticals Provides Update on New Drug Application Review of Vonoprazan for Erosive Esophagitis
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, today announced that the U.S. Food and Drug Administration (FDA) has...
Nov 23, 2022 06:07 pm ET
ROSEN, A LEADING, LONGSTANDING, AND TOP RANKED FIRM, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT
WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) resulting from allegations that Phathom may have issued...
Nov 08, 2022 05:00 pm ET
Phathom Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Updates
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the third quarter of 2022 and provided recent...
Nov 03, 2022 08:30 am ET
Phathom Pharmaceuticals to Participate in Upcoming Investor Healthcare Conferences
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, announced today that members of its management team will participate...
Nov 02, 2022 02:55 pm ET
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors With Losses to Inquire About Securities Class Action Investigation – PHAT
WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) resulting from allegations that Phathom may have issued...
Nov 01, 2022 08:00 am ET
Phathom Pharmaceuticals Announces Placement of the Remaining $40 Million in Non-Dilutive Capital under its up to $300 Million Revenue Interest Financing Agreement
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, today announced that up to an additional $40 million in non-dilutive...
Oct 24, 2022 08:00 am ET
Phathom Pharmaceuticals Completes Patient Enrollment in Phase 3 PHALCON-NERD-301 Daily Dosing Trial of Vonoprazan in Non-Erosive Gastroesophageal Reflux Disease (NERD)
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, today announced it has completed enrollment in its PHALCON-NERD Daily...
Oct 23, 2022 12:01 pm ET
Phathom Pharmaceuticals Presents New Data Evaluating First-in-Class Potassium-Competitive Acid Blocker (PCAB) Vonoprazan as Novel On-Demand Treatment in NERD at American College of Gastroenterology (A
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, announced today that detailed results from an investigational Phase 2...
Oct 18, 2022 08:00 am ET
Phathom Pharmaceuticals to Present Latest Data on Vonoprazan at American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, announced today the company will present new data and research at the...
Sep 26, 2022 08:00 am ET
Phathom Pharmaceuticals Appoints Dr. James Topper to its Board of Directors
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, today announced the appointment of James “Jamie” Topper, M.D., Ph.D.,...
Sep 07, 2022 08:15 am ET
Phathom Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, announced today that members of the management team will present...
Sep 06, 2022 09:15 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Singularity, Phathom, EyePoint, and Olo and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Singularity Future Technology Ltd. (NASDAQ: SGLY), Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT), EyePoint Pharmaceuticals,...
Aug 15, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating NIO, Discover, MINISO, and Phathom and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against NIO, Inc. (NYSE: NIO), Discover Financial Services (NYSE: DFS), MINISO Group Holding Limited (NYSE: MNSO), and Phathom...
Aug 10, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Phathom, TuSimple, Mercury Systems, and Cassava and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT), TuSimple Holdings, Inc. (NASDAQ: TSP), Mercury Systems, Inc. (NASDAQ: MRCY),...
Aug 10, 2022 07:15 pm ET
ROSEN, A LEADING LAW FIRM, Encourages Phathom Pharmaceuticals, Inc. Investors with Losses Exceeding $100K to Inquire About Securities Class Action Investigation – PHAT
WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) resulting from allegations that Phathom may have issued...
Aug 06, 2022 01:16 pm ET
ROSEN, A LEADING LAW FIRM, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT
WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) resulting from allegations that Phathom may have issued...
Aug 05, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating MINISO, Digital World, Verano, and Phathom and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against MINISO Group Holding Limited (NYSE: MNSO), Digital World Acquisition Corp. (NASDAQ: DWAC), Verano Holdings Corp. (OTCMKTS:...
Aug 04, 2022 09:00 pm ET
PHATHOM ALERT: Bragar Eagel & Squire, P.C. is Investigating Phathom Pharmaceuticals, Inc. on Behalf of Phathom Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Phathom Pharmaceuticals, Inc. (“Phathom” or the “Company”) (NASDAQ: PHAT) on behalf of Phathom stockholders. Our investigation concerns whether Phathom has violated the federal securities laws and/or engaged in other unlawful business practices.
Aug 04, 2022 03:19 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Phathom Pharmaceuticals, Inc. - PHAT
Pomerantz LLP is investigating claims on behalf of investors of Phathom Pharmaceuticals, Inc. (“Phathom” or the “Company”) (NASDAQ: PHAT).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext....
Aug 04, 2022 03:15 pm ET
Phathom Pharmaceuticals, Inc. Investors: Company Investigated by the Portnoy Law Firm
The Portnoy Law Firm advises Phathom Pharmaceuticals, Inc. (“Phathom” or the “Company”) (NASDAQ: PHAT) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. Phathom...
Aug 03, 2022 09:00 pm ET
PHATHOM ALERT: Bragar Eagel & Squire, P.C. is Investigating Phathom Pharmaceuticals, Inc. on Behalf of Phathom Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Phathom Pharmaceuticals, Inc. (“Phathom” or the “Company”) (NASDAQ: PHAT) on behalf of Phathom stockholders. Our investigation concerns whether Phathom has violated the federal securities laws and/or engaged in other unlawful business practices.
Aug 03, 2022 01:00 pm ET
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Phathom Pharmaceuticals, Inc. (PHAT) on Behalf of Investors
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Phathom Pharmaceuticals, Inc. (“Phathom” or the “Company”) (NASDAQ:
Aug 03, 2022 11:40 am ET
INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Phathom Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Phathom Pharmaceuticals, Inc. (“Phathom” or “the Company”) (NASDAQ:
Aug 03, 2022 10:00 am ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Phathom Pharmaceuticals, Inc. (PHAT) on Behalf of Investors
Law Offices of Howard G. Smith announces an investigation on behalf of Phathom Pharmaceuticals, Inc. (“Phathom” or the “Company”) (NASDAQ: PHAT) investors concerning the Company’s possible violations of federal securities laws.
Aug 02, 2022 08:48 pm ET
The Law Offices of Frank R. Cruz Announces Investigation of Phathom Pharmaceuticals, Inc. (PHAT) on Behalf of Investors
The Law Offices of Frank R. Cruz announces an investigation of Phathom Pharmaceuticals, Inc. (“Phathom” or the “Company”) (NASDAQ:
Aug 02, 2022 05:59 pm ET
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Phathom Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Phathom Pharmaceuticals, Inc. (“Phathom” or “the Company”) (NASDAQ:
Aug 02, 2022 04:53 pm ET
EQUITY ALERT: Rosen Law Firm Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Class Action Investigation – PHAT
WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) resulting from allegations that Phathom may have issued materially misleading business information to the investing public.
Aug 02, 2022 08:00 am ET
Phathom Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Updates
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the second quarter of 2022 and provided recent...
Jun 01, 2022 08:15 am ET
Phathom Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, announced today that members of the management team will participate...
May 25, 2022 08:00 am ET
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of Vonoprazan NDA for the Treatment of Erosive Esophagitis
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the U.S. Food and Drug Administration (FDA) has accepted for review...
May 24, 2022 12:15 pm ET
Phathom Pharmaceuticals Presents Data on Novel Potassium-Competitive Acid Blocker (PCAB) Vonoprazan from a Range of Studies at Digestive Disease Week® (DDW) 2022
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that results from multiple studies evaluating...
May 17, 2022 08:01 am ET
Phathom Pharmaceuticals to Present Data at DDW 2022 Annual Meeting
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), an innovative biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the company will present findings from multiple studies...
May 10, 2022 08:00 am ET
Phathom Pharmaceuticals Reports First Quarter 2022 Results and Provides Recent Clinical, Regulatory, and Business Updates
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the first quarter of 2022 and provided updates...
May 04, 2022 08:01 am ET
Phathom Pharmaceuticals Announces Revenue Interest Financing Agreement for Up to $260 Million in Non-Dilutive Capital
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced a revenue interest financing of up to $260 million in non-dilutive...
May 03, 2022 05:40 pm ET
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin) for the Treatment of H. pylori Infec
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the U.S. Food and Drug Administration (FDA) approved both VOQUEZNA™...
Apr 26, 2022 08:00 am ET
Phathom Pharmaceuticals Appoints Frank Karbe to its Board of Directors
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Frank Karbe to its Board of Directors. Mr. Karbe,...
Apr 01, 2022 08:01 am ET
Phathom Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will...
Mar 22, 2022 08:02 am ET
Phathom Pharmaceuticals Announces Appointment of Molly Henderson as Chief Financial and Business Officer
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Molly Henderson to the...
Mar 14, 2022 08:02 am ET
Phathom Pharmaceuticals Submits Vonoprazan NDA to FDA for the Treatment of Erosive Esophagitis
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that it has submitted a new drug application...
Mar 01, 2022 04:04 pm ET
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Pipeline and Business Progress
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the fourth quarter and full...
Feb 09, 2022 04:04 pm ET
Phathom Pharmaceuticals Announces Positive Topline Results from Phase 2 Trial Evaluating Vonoprazan for Non-Erosive Gastroesophageal Reflux Disease (NERD)
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported positive topline results from PHALCON-NERD, a Phase 2 study...
Nov 23, 2021 04:00 pm ET
Phathom Pharmaceuticals to Participate in the 4th Annual Evercore ISI HealthCONx Conference
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will...
Nov 12, 2021 04:30 pm ET
Phathom Pharmaceuticals to Participate in Two Upcoming Investor Healthcare Conferences
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of its management team will...
Nov 08, 2021 08:00 am ET
Phathom Pharmaceuticals Reports Third Quarter 2021 Results and Provides Key Clinical, Regulatory, and Business Updates
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the third quarter of 2021...
Oct 27, 2021 09:47 pm ET
Phathom Pharmaceuticals Withdraws Public Offering
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the withdrawal of the previously announced,...
Oct 26, 2021 04:01 pm ET
Phathom Pharmaceuticals Announces Proposed Public Offering of 5,000,000 Shares of Common Stock
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today an underwritten public offering of 5,000,000...
Oct 24, 2021 03:30 pm ET
Phathom Pharmaceuticals Announces New Data at ACG 2021 Annual Scientific Meeting
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today data from the PHALCON-HP Phase 3 study, the...
Oct 21, 2021 08:00 am ET
Phathom Pharmaceuticals to Present New Data at ACG 2021 Annual Scientific Meeting
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that data for vonoprazan, an investigational...
Oct 18, 2021 07:00 am ET
Phathom Pharmaceuticals Announces Positive Topline Results from PHALCON-EE Pivotal Phase 3 Erosive Esophagitis Trial
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that vonoprazan successfully met its primary...
Sep 27, 2021 08:00 am ET
Phathom Pharmaceuticals Announces Results from VONO-103, a Phase 1 Study Evaluating Gastric Acid Inhibition of Vonoprazan and Lansoprazole (PREVACID®)
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported results from VONO-103, a Phase 1 trial evaluating...
Sep 20, 2021 08:00 am ET
Phathom Pharmaceuticals Secures $200 Million Term Loan Facility from Hercules Capital
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported it has obtained a $200 million term loan facility...
Sep 08, 2021 08:00 am ET
Phathom Pharmaceuticals Submits Two NDAs to U.S. FDA for Vonoprazan-based Treatment Regimens for the Treatment of H. pylori Infection
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that it has submitted two new drug applications...
Aug 31, 2021 07:45 am ET
Phathom Pharmaceuticals to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that Terrie Curran, President and CEO, Azmi...
Aug 10, 2021 08:00 am ET
Phathom Pharmaceuticals Reports Second Quarter 2021 Results and Provides Update Regarding Key Clinical and Regulatory Milestones
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the second quarter of 2021...
Aug 05, 2021 07:30 am ET
Phathom Pharmaceuticals Mourns the Loss of Chairman and Founder, Tadataka "Tachi" Yamada, M.D.
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the sad news that its chairman and founder, Dr....
Aug 02, 2021 08:30 am ET
Phathom Pharmaceuticals to Participate in the BMO Biopharma Spotlight Series: Innovation in GI
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that Terrie Curran, Phathom’s President and...
May 25, 2021 04:01 pm ET
Phathom Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will...
May 11, 2021 08:00 am ET
Phathom Pharmaceuticals Reports First Quarter 2021 Results and Provides Recent Business Updates
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the first quarter of 2021...
May 06, 2021 05:48 pm ET
Phathom Pharmaceuticals to Present at the Bank of America Securities 2021 Virtual Healthcare Conference
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will...
Apr 29, 2021 04:01 pm ET
Phathom Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Trial of Vonoprazan in Helicobacter pylori (H. pylori) Infection; Study Met All Primary and Secondary Endpoints
based triple therapyNew Drug Application (NDA) submissions targeted for Q4 2021Phathom to host conference call and live webcast today, April 29, 2021 at 4:30 pm ET FLORHAM PARK, N.J., April 29, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals,...
Apr 06, 2021 08:00 am ET
Phathom Pharmaceuticals to Present at 20th Annual Needham Virtual Healthcare Conference
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will...
Mar 30, 2021 04:05 pm ET
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Pipeline and Business Progress
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the fourth quarter and full...
Jan 19, 2021 08:30 am ET
Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Helicobacter pylori (H. pylori) Trial
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it has completed patient enrollment in...
Dec 16, 2020 06:43 pm ET
Phathom Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the pricing of its underwritten public offering...
Dec 15, 2020 04:01 pm ET
Phathom Pharmaceuticals Announces Proposed Public Offering of 2,250,000 Shares of Common Stock
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that it intends to offer and sell, subject to...
Dec 14, 2020 08:30 am ET
Phathom Pharmaceuticals Announces Plans to Initiate Vonoprazan Development Program in Non-Erosive Reflux Disease (NERD)
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced plans to expand its vonoprazan development...
Nov 30, 2020 04:05 pm ET
Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Erosive Esophagitis Trial
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it has completed patient enrollment in...
Nov 27, 2020 08:00 am ET
Phathom Pharmaceuticals to Participate at Upcoming Investor Healthcare Conferences
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will...
Nov 19, 2020 04:05 pm ET
Phathom Pharmaceuticals to Host Virtual Investor Day
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today confirmed it will host a virtual Investor Day on December...
Nov 13, 2020 04:05 pm ET
Phathom Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will...
Nov 10, 2020 04:05 pm ET
Phathom Pharmaceuticals Reports Third Quarter 2020 Results and Provides Update on Phase 3 Trials
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the third quarter of 2020...
Nov 04, 2020 04:05 pm ET
Arcutis Announces Appointment of Terrie Curran to Board of Directors
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a medical dermatology company developing innovative treatments for patients with immune-mediated dermatological diseases and conditions, today announced that Terrie Curran has been appointed to the...
Sep 09, 2020 08:30 am ET
Phathom Pharmaceuticals to Present at Morgan Stanley 18th Annual Global Healthcare Conference
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will...
Aug 06, 2020 08:30 am ET
Phathom Pharmaceuticals Reports Second Quarter 2020 Results
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the second quarter of 2020....
Jul 13, 2020 08:30 am ET
Phathom Pharmaceuticals Announces Appointment of Todd Branning as Chief Financial Officer
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it has appointed Todd Branning as Chief...
Jun 15, 2020 08:30 am ET
Phathom Pharmaceuticals Provides Clinical Trial Status Update
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it has randomized the first new patients in...
May 28, 2020 04:30 pm ET
Phathom Pharmaceuticals to Present at Upcoming Investor Conferences
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that Terrie Curran, President and Chief...
May 12, 2020 08:30 am ET
Phathom Pharmaceuticals Reports First Quarter 2020 Results
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the first quarter of 2020....
Apr 09, 2020 04:30 pm ET
Phathom to Participate at the 19th Annual Needham Virtual Healthcare Conference
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that company management will participate in...
Mar 19, 2020 08:30 am ET
Phathom Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Clinical Trial Status and Business Updates
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the fourth quarter and full...
Feb 25, 2020 04:35 pm ET
Phathom Pharmaceuticals to Present at 40th Annual Cowen and Company Health Care Conference on March 2, 2020
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that Terrie Curran, President and Chief...
Jan 06, 2020 08:30 am ET
Phathom Pharmaceuticals Appoints Martin J. Gilligan as Chief Commercial Officer
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced the appointment of Martin J. Gilligan as Chief Commercial Officer. Mr. Gilligan most recently was Corporate Vice President at Celgene Corporation, where he led marketing, market access and business development for Celgene’s Inflammation and Immunology Franchise. He held key leadership roles in the launch and growth of OTEZLA® through its sale to Amgen for $13.4 billion.
Dec 23, 2019 08:30 am ET
Phathom Pharmaceuticals Announces Initiation of Pivotal Phase 3 Clinical Trial for Vonoprazan in Helicobacter Pylori (H. pylori) Infection
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the initiation of PHALCON-HP. In this pivotal Phase 3 clinical trial, clinicians will evaluate vonoprazan in combination with amoxicillin (vonoprazan dual therapy) and vonoprazan in combination with amoxicillin and clarithromycin (vonoprazan triple therapy) for the successful eradication of H. pylori infection. With the initiation of PHALCON-HP, vonoprazan is now being evaluated in two pivo
Dec 02, 2019 08:30 am ET
Phathom Pharmaceuticals Announces Initiation of Pivotal Phase 3 Clinical Trial for Vonoprazan in Erosive Esophagitis
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the initiation of PHALCON-EE, the Company’s pivotal Phase 3 clinical trial of vonoprazan for both the healing and maintenance of healing of erosive esophagitis (EE) as well as the relief of heartburn.
Dec 02, 2019 08:30 am ET
Phathom Pharmaceuticals Expands Leadership Team and Announces Board Transition
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today multiple executive appointments. As previously announced as part of the
Nov 26, 2019 08:30 am ET
Phathom Pharmaceuticals to Present at Evercore ISI 2019 HealthCONx Conference
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that Azmi Nabulsi, M.D., Chief Operating Officer, will present at the Evercore 2019 HealthCONx Conference on Tuesday, December 3 at 1:35 p.m. EST at the Four Seasons Hotel, Boston.
Nov 25, 2019 08:30 am ET
Phathom Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today its results for the third quarter ended September 30, 2019 and provided an update on recent corporate developments.
Nov 13, 2019 04:05 pm ET
Phathom Pharmaceuticals to Present at Jefferies 2019 London Healthcare Conference
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that David Socks, President and CEO, will present at the Jefferies 2019 London Healthcare Conference on Wednesday, November 20 at 10:40 a.m. GMT at the Waldorf Hilton, London.
Oct 29, 2019 04:05 pm ET
Phathom Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the closing of its previously announced initial public offering of 10,997,630 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 1,434,473 additional shares, at a public offering price of $19.00 per share. Including the option exercise, the gross proceeds to Phathom, before deducting underwriting discounts and commissions and estimated o
Oct 24, 2019 08:25 pm ET
Phathom Pharmaceuticals Announces Pricing of Initial Public Offering
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that it has priced its initial public offering of 9,563,157 shares of its common stock at a public offering price of $19.00 per share. The gross proceeds to Phathom, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $181.7 million. All of the common stock is being offered by Phathom. In addition, Phathom has granted the underw

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.